Prostate Cancer Diagnostics Market: Key Insights
Prostate cancer is prevalent cancer affecting men and is commonly diagnosed in older age. It occurs in the prostate gland, a small, walnut-shaped gland located below the bladder and in front of the rectum. Early detection of prostate cancer is critical as it is more treatable in its early stages.
The most common diagnostic tests to detect prostate cancer are the prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE). The PSA test measures the level of PSA in the blood, a protein produced by the prostate. An elevated level of PSA can be a sign of prostate cancer, but it can also result from other conditions, such as benign prostate enlargement. The DRE involves a doctor manually checking the prostate for any abnormalities or lumps.
Prostate Cancer Diagnostics Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage:by Type (Priliminary Tests and Confirmatory Tests), and Geography (North America, Europe, Asia Pacific, and South and Central America)
Prostate Cancer Diagnostics Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
Download Free Sample
Other diagnostic tests that can be used with the PSA and DRE include biopsy, transrectal ultrasound (TRUS), and magnetic resonance imaging (MRI). A biopsy removes a small tissue sample from the prostate to be examined under a microscope. TRUS uses sound waves to produce prostate images and can help determine the size, shape, and location of any abnormal growth. MRI uses a magnetic field and radio waves to produce detailed prostate images, which can help identify suspicious areas for biopsy.
In conclusion, early detection of prostate cancer is crucial for effective treatment and improved outcomes. The PSA and DRE are the most common diagnostic tests for prostate cancer, but other tests such as biopsy, TRUS, and MRI can also be used to confirm a diagnosis and determine the cancer stage. Men need to discuss their risk factors and screening options with their healthcare providers.
Growing Incidence of Obesity to Drive Prostate Cancer Diagnostics Market
Obesity is a rising concern among people across the world. Obesity leads to various chronic diseases, including cancers, cardiovascular diseases, and many more. It is said that obesity may lead to 13 different types of cancers. In many cases, obesity may become a factor in cancer relapse and result in fatality. Also, obesity is seen more among older men. Additionally, lifestyle changes are increasing obesity among working men. Moreover, men treated with prostate cancer generally become overweight, which may lead to prostate cancer reoccurrence.
The growth of the prostate cancer diagnostics market; is expected to continue in the coming years, driven by the increasing incidences of obesity. For instance, according to a research study published by Oxford Population Health in May 2022, prostate cancer is more common in men in the UK. Annually ~47, 5000 cases are diagnosed in the UK, and it is the second most common cause of death in men in the UK. Thus, it is expected that obesity in men may create prostate cancer. Additionally, the development of new techniques and technologies may create opportunities for prostate cancer diagnostics that will eventually lead to market growth.
Prostate Cancer Diagnostics Market: Segmental Overview
The global prostate cancer diagnostics market is segmented on the basis of type which is sub segmented as preliminary tests and confirmatory test. The confirmatory test segment is further sub segmented as PCA3 tests, transrectal ultrasound, and biopsy.
Based on type, the preliminary tests segment held a substantial share of the market. The market growth for preliminary tests is compelled by several aspects, including the increasing prevalence of chronic diseases, the need for early disease detection, and the advancements in medical technology. The growing demand for cost-effective and efficient diagnostic tests, combined with the increasing awareness of the importance of preventive health measures, has also contributed to market growth. The increasing number of regulatory approvals and the development of innovative diagnostic technologies and techniques are expected further to drive the market's growth in the coming years.
Prostate Cancer Diagnostics Market: Competitive Landscape and Key Developments
MDxHealth; Telo Genomics Corp (3D Signatures); Genomic Health, Inc; Abbott; OPKO Health; Siemens Healthcare; DiaSorin; BioMerieux; Roche; and Danaher Corporation (Beckman Coulter, Inc), among the key players operating in the prostate cancer diagnostics market. These companies have a widespread presence worldwide, which provides lucrative opportunities to serve a large number of customers and expand the prostate cancer diagnostics market.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com